Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Medical Genomics

Fig. 1

From: Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines

Fig. 1

Overview of Patient-Derived Xenograft (PDX) model generation and genomic characterization at The Jackson Laboratory (JAX). a Schematic overview of PDX model generation and characterization for the JAX PDX resource. JAX has generated, clinically annotated, and genomically characterized 455 PDX cancer models originating from 34 different primary sites (as of 05/08/2019) using the immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (aka, NSG™) mouse as the host strain. b Schematic of the genomic characterization of PDX models (see Methods for details). The three primary genomic characterization methods are: 1) somatic mutations using the JAX Cancer Treatment Profile™ (CTP,, the Illumina TruSeq™ panel or whole-exome sequencing, 2) DNA copy-number variation using Affymetrix SNP 6.0 arrays, and 3) gene expression profiles from Affymetrix microarrays or RNA sequencing (Illumina HiSeq)

Back to article page